Toxicity Profile of Antibody-Drug Conjugates in Breast Cancer: Practical Considerations

    July 2023 in “ EClinicalMedicine ”
    A. D’Arienzo, Annarita Verrazzo, Martina Pagliuca … Filippo Montemurro
    Studysummary This review discusses the toxicities associated with antibody-drug conjugates in breast cancer treatment and proposes strategies for monitoring and managing these adverse effects, but it reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on thelancet.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Optimizing Treatment Management of Trastuzumab Deruxtecan in Clinical Practice of Breast Cancer ESMO Open · 2022
    2. Prevention And Management Of Dermatological Toxicities Related To Anticancer Agents: ESMO Clinical Practice Guidelines Annals of Oncology · 2020
    3. Scalp Cooling to Prevent Chemotherapy-Induced Alopecia Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia · 2020
    4. Dermatological Adverse Events with Taxane Chemotherapy European Journal of Dermatology · 2016